Correlation Engine 2.0
Clear Search sequence regions


  • b t cell receptor (1)
  • BCR (3)
  • CD40 (2)
  • CD40LG (1)
  • gene (1)
  • immunoglobulin genes (1)
  • patients (5)
  • receptor (1)
  • rna (1)
  • t (3)
  • therapies (1)
  • tumor sites (2)
  • Sizes of these terms reflect their relevance to your search.

    Tumor heterogeneity complicates biomarker development and fosters drug resistance in solid malignancies. In lymphoma, our knowledge of site-to-site heterogeneity and its clinical implications is still limited. Here, we profiled two nodal, synchronously-acquired tumor samples from ten follicular lymphoma patients using single cell RNA, B cell receptor (BCR) and T cell receptor sequencing, and flow cytometry. By following the rapidly mutating tumor immunoglobulin genes, we discovered that BCR subclones were shared between the two tumor sites in some patients, but in many patients the disease had evolved separately with limited tumor cell migration between the sites. Patients exhibiting divergent BCR evolution also exhibited divergent tumor gene expression and cell surface protein profiles. While the overall composition of the tumor microenvironment did not differ significantly between sites, we did detect a specific correlation between site-to-site tumor heterogeneity and T follicular helper (Tfh) cell abundance. We further observed enrichment of particular ligand-receptor pairs between tumor and Tfh cells, including CD40 and CD40LG, and a significant correlation between tumor CD40 expression and Tfh proliferation. Our study may explain discordant responses to systemic therapies, underscores the difficulty of capturing a patient's disease with a single biopsy, and furthers our understanding of tumor-immune networks in follicular lymphoma. Copyright © 2021 American Society of Hematology.

    Citation

    Sarah Elena Haebe, Tanaya Shree, Anuja Sathe, Grady Day, Debra K Czerwinski, Susan Grimes, HoJoon Lee, Michael S Binkley, Steven R Long, Brock Aaron Martin, Hanlee P Ji, Ronald Levy. Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma. Blood. 2021 Mar 16


    PMID: 33728464

    View Full Text